Chemical.AI
智化科技
Chemical.AI (武汉智化科技) is an AI-enabled chemical synthesis platform founded in 2018 by CEO Ning Xia, a French Academy of Sciences PhD in organic chemistry with dual expertise in chemistry and computer science . The company applies artificial intelligence and chemical big data to solve preclinical synthesis problems in drug R&D, positioning itself as an early mover in China's AI-powered chemical synthesis segment .
The company raised nearly $15 million in a Series A+ round led by Source Code Capital in August 2021, with participation from Sequoia China, FreeS Fund, and Huafang Capital, following a 2019 angel round from FreeS Fund and a 2021 Series A led by Sequoia China Seed Fund . FreeS Fund's Wang Yikai recalled making the investment decision within roughly 30 minutes after visiting Xia's Wuhan office in March 2019 .
Chemical.AI's commercial trajectory has been shaped by close ties to WuXi AppTec. Xia first connected with WuXi executives in 2016, demonstrated his software to a roomful of their senior leaders, and secured the company's earliest commercial partnership through that engagement; WuXi later referred a client that became a $1 million-plus contract for AI retrosynthesis . The company has also established strategic partnerships with Keen Therapeutics and counts XtalPi among collaborators in pharma R&D projects . FreeS Fund has described it as having grown into a leading player in AI-assisted chemical synthesis with products deployed at global top-tier pharmaceutical firms .
AI-generated — may contain errors, please verify.
Coverage
AI for Pharmaceutical Chemical Synthesis: Can Today's AI Match a Chemist with 10 Years of Experience?
AI for Science is becoming one of the hottest directions in the primary market.
Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
The 6 Questions Young People Care About Most: We Asked 17 Founders | FreeS Fund Youth Festival & Graduation Season Special
Passion and conviction are what carry you through the darkness.
How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
Heading Into the Next Spring Amid Winter: 7 Early-Stage Companies Raise Nearly 600 Million RMB | FreeS Family Funding News · Vol 13
Looking forward to working alongside more outstanding founders.
MaHui Entrepreneurs | AI4S Industrialization Roundtable: With So Many Application Scenarios, "AI Tools" Will Deliver Greater Value
Code View | Yungang Huang: How Does AI4S Land in Different Stages, Industries, and Markets?
Yungang Huang Named to "Top 10 Young Partners"
"Partner on the Entrepreneurial Journey"
Code Mark | AI Breakthrough in Chemical Retrosynthesis, Chemical.AI's Performance Nears Decade-Experienced Chemist Level
AI-Powered Smarter, More Efficient Retrosynthetic Route Design
Farewell to a Year of Inflection Points: Will 2022 Be Better? | Li Feng's New Year Outlook
Where the heart leads, steady steps take you far.
"There Will Come a Moment When Technology Defeats Human Experience" | A Conversation with FreeS Fund
"There will come a moment when technology surpasses human experience."
FreeS Fund Earns Ten Honors from Zero2IPO, PEDaily, ChinaVenture & GEW, CVCRI, ChinaRong360, Wanbang RB, and Lancha Consumer | FreeS Matters
Continuously hiring investors
Live at 10 AM Tomorrow | New Opportunities in the Changing Landscape of Drug R&D
See you tomorrow at 10 a.m. sharp.
How Should We Think About the Present and Future of Drug R&D? | FreeS Fund Dialogue Vol. 2 — Final 2 Days to Register
What new variables and opportunities are emerging in the drug development industry?
FreeS Fund Report 25: Food Investment Through the Lens of China's Dietary Structure
What will we eat in the future?
New Opportunities Amid the Great Transformation in Drug R&D | FreeS Fund Dialogue Session 2 Now Open for Registration
Breakthroughs and Acceleration in New Drug R&D
Source Code Capital portfolio company "ONES" announces $50 million Series C round, with existing investor Source Code Capital continuing to increase its stake
Dedicated to building R&D management systems tailored to the needs of Chinese tech companies.
Source Code Capital portfolio company HAI ROBOTICS raises over $200 million across two rounds, with existing shareholder Source Code Capital continuing to increase its stake
Accelerating its global expansion, the company's operations now span more than 30 countries and regions across five continents.
Source Code Capital portfolio company Keenon Robotics announced the completion of a $200 million Series D funding round. Source Code Capital led the company's Series B round.
Dedicated to providing intelligent autonomous delivery solutions for enterprises worldwide.
Biotech Firms Raise Nearly 4 Billion Yuan, Consumer Companies Land Over 1.4 Billion | FreeS Family Funding Roundup · August
We've also released three short videos this week — follow us to check them out.
Soluble Microneedle Technology Company Youwei Biology Completes Tens of Millions of Yuan in Series A Financing Led by Source Code Capital
Effortless, painless drug delivery through a simple patch application.
Chemical.AI, an intelligent chemical synthesis platform, announced the completion of a nearly $15 million Series A+ funding round led by Source Code Capital.
Dedicated to solving new drug synthesis problems through artificial intelligence and chemical big data
FreeS Fund 2021 Outlook ② | Three Trends in Biomedical Innovation
The Biopharma Industry Enters the "Three Fast" Era
Why Is AI Drug Discovery So Hot, and Why Now? | FreeS Fund Biomedical VC Summit Transcript
Why We're Bullish on AI Drug Discovery
Why Is AI Drug Discovery So Hot? And How Long Will It Stay Hot? | FreeS Fund Events & Research Recs
Three Slightly Brain-Burning Little Gifts
Supporting the Fight Against the Novel Coronavirus: Our Actions and Call to Action | FreeS Fund
Let's come together and help the people of Hubei get through this difficult time.
